Alternatively, although not previously reported in patients with JAK2 exon 12 mutations, the patient may have a proportion of cells in the PBMNC population in which both alleles are mutated.
While we have detected an identical JAK2 mutation in two patients (PV31 and PV63) and a similar mutation in patient PV64, disease presentation and progression varied considerably between the patients (Table 1 ). PV31 presented with mildly elevated haemoglobin (Hgb) at an early age (32 years). The average age of diagnosis of JAK2V617F-positive patients in our cohort is 63.05711.85 years, range 40-84 years (n ¼ 40). Bone marrow cytogenetic analysis was normal, although the marrow was hypercellular with mild dysplastic changes of the megakaryocytes. Thromboembolic complications or other evidence of progressive disease remained absent in this patient 4 years after PV diagnosis. Patient PV63 had pre-existing chronic obstructive lung disease and presented at age 84 years with markedly elevated haemoglobin. The patient was started on regular venesections but developed deep-vein thrombosis (DVT) after 2 months. Of note, platelet levels were increasing during this time (from 310 to 618 Â 10 9 l
À1
), although the patient developed iron deficiency, presumably due to the phlebotomy therapy. Hydroxyurea and warfarin anticoagulation therapy resolved the DVT and blood counts normalized upon cessation of venesections, however the patient died as a result of respiratory failure 6 months after PV diagnosis without evidence of pulmonary embolism. The diagnosis of PV in this patient had been made without a BM biopsy but, interestingly, a trephine taken 4 years earlier to investigate pyrexia of unknown origin showed trilineage hyperplasia, small megakaryocyte clusters located close to the trabeculae and mild fibrosis. This is consistent with progression of the MPD to clinically symptomatic disease over a number of years. Patient PV64 presented at 68 years of age with marked erythrocytosis. Interestingly, this patient was thrombocytopenic at presentation and this persisted throughout the course of the disease despite steroid therapy (platelet count varied between 18-119 Â 10 9 l À1 ). Approximately 2 years after presentation, the patient developed marked leukocytosis (WCC 24.0 Â 10 9 l
). A BM biopsy at this time was hypercellular with some dysplastic features, although megakaryocytes were decreased, consistent with the thrombocytopenia seen in this patient. A second BM biopsy, 2 months later (which provided the sample for this study) showed similar findings and with moderate fibrosis reported. The patient progressed to development of acute myeloid leukaemia (AML) within one year and died some months later. Thus, while PV31 and several other patients reported with JAK2 exon 12 mutations are of early onset and generally present with platelet, leukocyte and granulocyte counts within the normal range, 4,5 patients PV63 and PV64 presented with multilineage disease of late onset associated with thrombo-embolic complications (DVT) and rapid transformation to AML, respectively. Furthermore, other modifying factors extrinsic to the haematopoietic system such as coexistent lung disease and chronic inflammation, may be important in the manifestation of disease involving JAK2 exon 12 mutations and, as suggested by Pardanani et al., 5 the specific classification of disease based on alternative JAK2 mutations should be carefully considered as further patients are described. Acute monoblastic leukemia is characterized by a monocytic differentiation blockage, resulting in the accumulation of immature monoblastic-like cells in bone marrow and circulating blood. Also designated as AML5, this acute myeloid leukemia (AML) subtype, which accounts for about 20% of adult AML cases, poorly responds to chemotherapy, and its association with hyperleukocytosis, extramedullary involvement and coagulation abnormalities contributes to its bad prognosis. AML5 blasts display high levels of the CD44 antigen, a highly glycosylated transmembrane adhesion molecule that is the main cellular receptor of hyaluronic acid. CD44 is also a signalling receptor involved in many cellular functions, including myeloid differentiation. 1 We have previously shown that specific function-activating monoclonal antibodies (mAbs) to CD44 are capable of triggering the differentiation of AML5 blasts towards monocytic lineage. 2 This differentiation was evidenced by the expression of lineage antigens (CD11b and CD14), the ability to produce oxidative bursts and cytological modifications, all specific to differentiated monocytes. 2 These results have led us to develop a CD44-targeted differentiation therapy that could be as efficient in AML5 as the retinoic acid-based differentiation therapy in the promyelocytic AML subtype. However, a comprehensive development of this CD44-targeted therapy of AML5 requires to better understand the mechanisms sustaining the CD44-induced differentiation process.
CM
It is now well established that an important function of CD44 in normal macrophages (when ligated with hyaluronic acid or with specific mAbs) is to induce the synthesis of cytokines (interleukin (IL)-1b, IL-6, IL-12, tumor necrosis factor, granulo- Table 1 Increase of cytokine and chemokine gene expression in CD44-ligated AML5 blasts Median intensity (arbitrary units) of hybridized cDNA calculated from 13 AML5 samples. c Gene expression intensities of P245-and IgG1-treated blasts were compared by using the non-parametric Wilcoxon sign rank test. Differences were considered as statistically significant for Pp0.05. Ratio of (P245-treated/control) median intensity of hybridized cDNA spots (n ¼ 13). Figure 1 (a) mRNA expressions of interleukin (IL)-1a and IL-1b, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-8 genes in CD44-ligated and control acute myeloid leukemia (AML5) blasts. mRNA levels were measured in 10 primary AML5 samples, incubated for 24 h with the anti-CD44 monoclonal antibody (mAb) P245 or with IgG1 (controls). Real-time reverse transcription-PCR was performed using primer sequences and fluorescent FAM probes selected and provided by Applied Biosystems (Foster City, CA, USA). The 'housekeeping' gene ABL was used as an internal standard. Each sample was run in duplicate, and the mean value was expressed as cycle threshold (C T ). cyte-macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF)) and chemokines (IL-8, macrophage inflammatory protein (MIP)-1a and MIP1b). 3, 4 Interestingly, some of these cytokines and chemokines are involved in the monocytic differentiation of normal hematopoietic progenitors (IL-1b, IL-6, GM-CSF, M-CSF and IL-8) and, even more, can induce the differentiation of some leukemic cells (IL-1, IL-6 , GM-CSF and G-CSF). 5 These considerations prompted us to ask whether CD44 ligation triggers in AML5 blasts the synthesis of cytokines and chemokines contributing to their differentiation.
To answer this question, we incubated leukemic blasts (5 Â 10 5 cells ml
À1
) isolated from peripheral blood of 13 AML5 patients at diagnosis, with 50 mg ml -1 of the anti-CD44 mAb P245 (a gift from Dr L Boumsell, Inserm). Control cells were simultaneously incubated with the same amount of IgG1. After 24-h incubation, gene expression profiling was analyzed using BD Atlas cDNA Expression Arrays (BD Biosciences Clontech, Mountain View, CA, USA), which include 83 cytokine/chemokine cDNAs spotted on nylon membrane (available on Clontech's website: http://www.clontech.com/ support/tools.asp?product_tool_id ¼ 157578&tool_id ¼ 157579 and 634511_Hu.xls). RNA extraction, reverse transcription and 32 P-labelled cDNA hybridization were simultaneously performed in treated and control samples, under standard conditions according to the manufacturer's instructions. To eliminate the variability due to sample labelling or due to exposure duration, data from each array experiment were normalized by the median value of all spot intensities on the given membrane. The results, shown in Table 1 , evidenced that the hybridization spot intensities of 19 cytokine/chemokine genes were significantly increased in CD44-ligated AML5 blasts compared to controls (Pp0.05, non-parametric Wilcoxon sign rank test).
Interestingly, these genes comprised GM-CSF, IL-1b and IL-6 (1.4-, 7.3-and 1.5-fold increased, respectively), which have been reported to induce monocytic differentiation of some leukemic cells. 5 Therefore, we asked whether these cytokines also contribute to the CD44-triggered differentiation of AML5 blasts. In addition, considering that IL-8 gene expression was the most strikingly increased (15.2-fold) in CD44-ligated AML5 blasts, we also investigated whether this chemokine had a role in the differentiation process. First we confirmed, by real-time reverse transcription-PCR analysis, that the mRNA expression of these genes was significantly increased (Pp0.05, Wilcoxon sign rank test) (Figure 1a) . Then, using enzyme-linked immunosorbent assay, we evidenced that GM-CSF, IL-1b, IL-6 and IL-8 were secreted by CD44-ligated AML5 blasts: as shown in Figure 1b , their culture media comprised, at 24 h after addition of the P245 mAb, up to 180 pg ml À1 GM-CSF, 275 pg ml À1 IL-1b and 475 pg ml À1 IL-6 (median values). In contrast, no GM-CSF, and only very little IL-1b (15 pg ml À1 ) and IL-6 (9 pg ml À1 ) (median values) were detected in controls. Besides, the level of IL-8 was 100-fold increased (179 000 vs 1678 pg ml À1 in controls). Finally, we investigated whether the functional inhibition of GM-CSF, IL-1b, IL-6 or IL-8 inhibited the differentiation of CD44-ligated AML5 blasts. Blasts from seven AML5 patients were preincubated for 1 h with specific mAbs to GM-CSF, to IL-6 or to IL-8 receptors, or with the IL-1 receptor antagonist protein IL-1RA. Then, they were treated with the P245 mAb and their differentiation was analyzed at day 3, by measuring the increase in the expression of CD11b and CD14 differentiation antigens. 2 As shown in Figure 1c , increase in the expression of CD14 was fully abrogated by functional inhibition of either GM-CSF or IL-8, whereas inhibition of IL-1b or IL-6 had no significant effect. In addition, the increase in the expression of CD11b was unaffected by either treatment (data not shown). It has been demonstrated that the acquisition of CD11b precedes that of CD14 in the course of monocytic differentiation of either normal precursors 6, 7 or CD44-ligated AML5 blasts. 2 Accordingly, the present results indicate that the early stages of CD44-induced differentiation are independent of GM-CSF, IL1b, IL-6 and IL-8 synthesis, whereas the late stages require GM-CSF and IL-8. Supporting these conclusions, we have noticed that GM-CSF, IL-1b, IL-6 and IL-8 are not able to induce AML5 blast differentiation when they are used alone, at similar doses as those secreted by the CD44-ligated blasts. The early differentiation-inducing events triggered by CD44 ligation remain to be identified. As a hypothesis, one of these early events may be the inhibition of monocytic differentiation inhibitors c-myb and CDP (CCAAT displacement protein), whose gene expression is significantly inhibited in CD44-ligated AML5 blasts (cDNA array analysis, data not shown).
In conclusion, our work shows for the first time that autocrine/ paracrine secretion of GM-CSF and IL-8 is required for the achievement of CD44 ligated AML5 blast differentiation. This suggests that combining GM-CSF and IL-8 with CD44-targeting may be clinically effective, since it may increase the extent of differentiation. The burst of cytokine/chemokine synthesis may provoke a macrophage activation syndrome, but it might be possible to control it, as in retinoic acid-treated promyelocytic leukemia. Interestingly, IL-8 and GM-CSF are known to stimulate the release of normal hematopoietic stem cells from their bone marrow niche (mobilization process). 8 Similarly, IL-8 and GM-CSF may stimulate the release of leukemic stem cells from their niche. Since maintenance of leukemic stem cells is niche-dependent, we suggest, as a working hypothesis, that IL-8 and GM-CSF may contribute to the eradication of leukemic stem cells by P245, as we recently reported in human AML-xenografted mice. 
